WATCH-> CEL-SCI Corporation (CVM) NYSE American - Nasdaq Real Time Price. 3.8600-0.0800 (-2.0305%) As of 09:36AM EDT.
I respect Adam F alot he went very negative. I also have along long history with this Co they are a shade shady. The CEO talks very freely. Today's breathless news- CEL-SCI says Multikine reduced and eliminated tumors 08:52 CVM CEL-SCI Corporation issued the following letter to its shareholders. "The Phase 3 study of our investigational cancer immunotherapy, Multikine , was the largest advanced primary head and neck cancer study ever conducted. We built a full-scale manufacturing facility and spent 10 years and over $100M because we were convinced that our Multikine could help these very sick patients. Our successful results are unprecedented for a disease that has not seen a survival benefit from treatment in decades. Multikine Reduced and Eliminated Tumors Within Three Weeks and Before Surgery The most important result of our study is this: 16% of Multikine patients in the radiation-only group in our Phase 3 study had at least a 30% tumor reduction within just a few weeks of treatment before surgery. Five of these responders had their tumors completely disappear before surgery. Think about that for a minute. These patients presented with advanced primary disease, and within three weeks of Multikine treatment, before surgery, their tumors were gone. " Over a week ago CEL-SCI's Multikine 'not getting approved,' STAT's Feuerstein says 08/19 CVM STAT's Adam Feuerstein said via Twitter: $CVM posted results from Multikine ph3 study on clinicaltrials less thandotgreater than gov today, confirming the failure. Median Overall Survival: Multikine 46.3 months; Placebo 52.9 months. Placebo patients lived longer. This drug is not getting approved, anywhere...Also, $CVM incessant hand-waving about a Multikine benefit observed in lower-risk patients is a non-starter. The analysis was post-hoc data mining and will be thrown out by any regulatory agency that sees it. If Cel-Sci actually files, ever..." Shares of CEL-SCI are up 9% to $4.60 in midday trading. Reference Link Show Related Items >>
Oh Fuck are we not trading? (BCYC)- this looks weird no bid/ask? Previous Close 25.30 Open 25.04 Bid N/A x N/A Ask N/A x N/A
Going a good deal higher-- Start making a list of companies over their 200 & 50 day..... and put SQM on it! Going to $111+ Sociedad Química y Minera de Chile S.A. (SQM) NYSE - Nasdaq Real Time Price. 104.48+0.77 (+0.74%)
DICE Therapeutics, Inc. (DICE) NasdaqGM - NasdaqGM Real Time Price. 19.89+0.93 (+4.93%) As of 10:00AM EDT. Market open.
WATCH-DIS Disney (DIS) is gearing up this week to unveil what's in store for the media and entertainment conglomerate with its Disney+ Day on Thursday and D23 Expo later in the week. Disney stock rose early Wednesday. Look for the Disney+ Day to update investors and fans alike on the company's streaming slate, including the much-anticipated debut of "Marvel's Thor: Love and Thunder" and the Sept. 8 premiere of the live-action version of the classic "Pinocchio," starring Tom Hanks as Gepetto. An ad-free Disney+ subscription is set to increase to $10.99 a month from $7.99 in November. That's no surprise, considering an industrywide subscription growth slowdown amid soaring production costs for new content. Disney also will introduce an ad-supported, lower-priced tier, something rival Netflix (NFLX) also is working on. Meanwhile, Disney's multiday D23 Expo will feature presentations on its media businesses, theme parks and cruises, with product reveals and sneak peeks. The event runs from Sept. 9 to 11.